Published in

MDPI, Journal of Clinical Medicine, 11(8), p. 1832, 2019

DOI: 10.3390/jcm8111832



Export citation

Search in Google Scholar

2017 ACC/AHA Blood Pressure Classification and Cardiovascular Disease in 15 Million Adults of Age 20–94 Years

Journal article published in 2019 by Hokyou Lee ORCID, So Mi Jemma Cho, Jong Heon Park, Sungha Park, Hyeon Chang Kim
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO


The 2017 American College of Cardiology/American Heart Association (ACC/AHA) high blood pressure (BP) guideline lowered the cut-off for hypertension, but its age-specific association with cardiovascular disease (CVD) remains inconclusive in different populations. We evaluated the association between high BP according to the 2017 ACC/AHA guideline and CVD risks in Koreans aged 20–94 years. In a nationwide health screening cohort, we included 15,508,537 persons aged 20–94 years without prior CVD. BP was categorized into normal, elevated, stage 1 hypertension, or stage 2 hypertension. The primary outcome was a composite CVD hospitalization (myocardial infarction, stroke, and/or heart failure). Over 10 years of follow-up, CVD incidence rates per 100,000 person-years were 105.4, 168.3, 215.9, and 641.2 for normal, elevated BP, stage 1, and stage 2 hypertension, respectively. The age-specific hazard ratios of stage 1 hypertension compared to normal BP were 1.41 (1.34–1.48) at ages 20–34, 1.54 (1.51–1.57) at ages 35–49, 1.38 (1.35–1.40) at ages 50–64, 1.21 (1.19–1.24) at ages 65–79, and 1.11 (1.03–1.19) at ages 80–94 years. With the lowered BP cut-off, 130/80 mmHg, population attributable fraction for CVD was 32.2%. In conclusion, stage 1 hypertension was significantly associated with a higher CVD risk across entire adulthood. The new definition of hypertension may have a substantial population impact on primary CVD prevention.